Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Elective lymph node dissection in primary malignant melanoma]

J Petres1, R Rompel, P Büttner

  • 1Hautklinik der Städtischen Kliniken, Kassel.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ESMO open·2025
Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same journal

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Viral infections of the skin].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Viral exanthems in children].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Erratum to: Digital health applications and data protection].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Virus-induced exanthems in returning travellers].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Venous ulcus cruris-Surgical treatment].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
See all related articles

Elective lymph node dissection (ELND) improves disease-free survival for malignant melanoma patients, especially those with intermediate tumor thickness. This surgical approach offers significant benefits for specific patient groups.

Area of Science:

  • Oncology
  • Surgical Oncology

Context:

  • Malignant melanoma management remains a significant challenge in oncology.
  • The role of elective lymph node dissection (ELND) in primary malignant melanoma is a subject of ongoing debate and research.

Purpose:

  • To evaluate the impact of ELND on survival and disease-free survival in patients with primary malignant melanoma of the trunk and extremities.
  • To compare outcomes between wide local excision (WLE) plus ELND versus WLE alone.

Summary:

  • A matched-pair analysis of 750 patients (375 in each group) found no significant difference in overall survival between WLE + ELND and WLE alone.
  • However, the WLE + ELND group demonstrated a significantly higher disease-free interval (P < 0.05).
  • For patients with intermediate tumor thickness (1.51-4.0 mm), WLE + ELND showed improved disease-free survival (P < 0.001) and a non-significant trend towards increased survival rates (P = 0.14), with particular benefit observed in male patients.

Related Experiment Videos

Impact:

  • The findings suggest that ELND may improve outcomes for malignant melanoma, particularly for patients with intermediate tumor thickness.
  • This study supports the utility of ELND in refining treatment strategies for specific malignant melanoma patient cohorts.
  • Results align with existing research highlighting ELND's positive influence on disease recurrence in select melanoma cases.